Mark A. Reed

Robin Hood Ventures (RHV) is a venture capital firm founded in 1999 by Rob weber. The firm is headquartered in Philadelphia, Pennsylvania.

DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada.

Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland.

IVAX LLC discovers, develops, manufactures, and markets generic pharmaceuticals, respiratory drugs, and cancer treatments. It offers drugs for the treatment of multiple sclerosis, brain cancer, asthma, and epilepsy. The company was founded by Phillip Frost and Jane H. Hsiao in 1985 and is headquartered in Weston, FL.

Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA.

Therakos, Inc. develops immune cell therapies delivered through extracorporeal photopheresis. The firm’s engineers, clinicians and biological researchers have been driven to discover new technologies and therapeutic applications that empower the immune response and improve patient outcomes. It supports clinicians by providing products and training to enhance the treatment of cutaneous T-cell lymphoma (CTCL) and by pursuing additional approved indications for autologous immune cell therapy. The company was founded in 1984 and is headquartered in West Chester, PA.

The Biotechnology Greenhouse Corp. of Southeastern PA (BioAdvance) is a venture capital firm founded in 2002. The firm is headquartered in Philadelphia, Pennsylvania.

Annovis, Inc. develops, manufactures, and markets a wide variety of nucleic acid based for the life sciences sector. The company is headquartered in Aston, PA.

Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA.

Mid-Atlantic Angel Group operates as a alternative investment manager. The company is headquartered in Philadelphia, PA.

Mallinckrodt LLC is proud to be one of the world's largest suppliers of both controlled substance pain medication and acetaminophen and to have over a century of leadership in helping to diagnose disease through imaging procedures. They are focused on innovative research and development programs, strong clinician relationships and a collaborative approach to new business opportunities. In short, they aim to lead a new generation of patient care by pursuing better, safer, more cost effective ways of diagnosing and treating disease to improve patient outcomes.

Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY.

Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.

Q-RNA, Inc. develops drugs for the treatment of Alzheimer's disease. The company was founded on August 30, 2002 and is headquartered in New York, NY.